$SLDB
Solid Biosciences Inc.

2023 Q2 Form 10-Q Financial Statement

#000095017023020851 Filed on May 11, 2023

View on sec.gov

Income Statement

Concept 2023 Q2 2023 Q1 2022 Q1
Revenue $0.00 $0.00 $1.925M
YoY Change -100.0% -100.0% -42.37%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $7.129M $7.399M $7.352M
YoY Change 4.06% 0.64% 22.13%
% of Gross Profit
Research & Development $19.78M $24.63M $19.95M
YoY Change -14.68% 23.49% 40.4%
% of Gross Profit
Depreciation & Amortization $703.0K $703.0K $709.0K
YoY Change -2.63% -0.85% -3.41%
% of Gross Profit
Operating Expenses $26.84M $32.03M $27.30M
YoY Change -14.92% 17.34% 34.99%
Operating Profit -$26.84M -$32.03M -$25.37M
YoY Change 5.76% 26.24%
Interest Expense $1.949M $1.678M
YoY Change
% of Operating Profit
Other Income/Expense, Net $2.214M $1.960M $44.00K
YoY Change 663.45% 4354.55% -414.29%
Pretax Income -$24.63M -$30.07M -$25.33M
YoY Change -1.85% 18.72% 49.87%
Income Tax $0.00 $0.00 $0.00
% Of Pretax Income
Net Earnings -$24.63M -$30.07M -$25.33M
YoY Change -1.85% 18.72% 49.87%
Net Earnings / Revenue -1315.74%
Basic Earnings Per Share -$1.25 -$1.54 -$3.37
Diluted Earnings Per Share -$1.25 -$1.54 -$224.9K
COMMON SHARES
Basic Shares Outstanding 19.60M 19.57M 7.507M
Diluted Shares Outstanding 19.66M 19.57M 7.507M

Balance Sheet

Concept 2023 Q2 2023 Q1 2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $160.2M $185.5M $180.1M
YoY Change -1.65% 3.03% -32.94%
Cash & Equivalents $91.57M $164.6M $129.7M
Short-Term Investments $68.62M $20.86M $50.34M
Other Short-Term Assets $7.283M $5.095M $18.54M
YoY Change -3.61% -72.52% 237.16%
Inventory
Prepaid Expenses
Receivables $14.00K
Other Receivables $0.00
Total Short-Term Assets $167.5M $190.6M $198.6M
YoY Change -1.74% -4.03% -27.59%
LONG-TERM ASSETS
Property, Plant & Equipment $7.391M $8.607M $6.097M
YoY Change 7.95% 41.17% -18.28%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $181.0K $238.0K $2.129M
YoY Change -58.68% -88.82% 609.67%
Total Long-Term Assets $37.25M $38.98M $8.948M
YoY Change -2.13% 335.67% -18.54%
TOTAL ASSETS
Total Short-Term Assets $167.5M $190.6M $198.6M
Total Long-Term Assets $37.25M $38.98M $8.948M
Total Assets $204.7M $229.6M $207.6M
YoY Change -1.81% 10.61% -27.24%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.968M $5.595M $4.761M
YoY Change -41.91% 17.52% 49.06%
Accrued Expenses $10.51M $12.38M $9.440M
YoY Change -34.89% 31.19% 38.95%
Deferred Revenue $6.170M
YoY Change -42.13%
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $419.0K $396.0K $239.0K
YoY Change 1.7% 65.69% 19.5%
Total Short-Term Liabilities $15.87M $20.29M $21.74M
YoY Change -26.95% -6.67% -4.63%
LONG-TERM LIABILITIES
Long-Term Debt $1.482M $1.596M $231.0K
YoY Change 590.91% -53.8%
Other Long-Term Liabilities $23.65M $23.91M $70.00K
YoY Change -3.66% 34060.0% -99.22%
Total Long-Term Liabilities $25.13M $25.51M $301.0K
YoY Change 2.38% 8374.42% -96.83%
TOTAL LIABILITIES
Total Short-Term Liabilities $15.87M $20.29M $21.74M
Total Long-Term Liabilities $25.13M $25.51M $301.0K
Total Liabilities $40.99M $45.80M $22.05M
YoY Change -11.39% 107.76% -31.75%
SHAREHOLDERS EQUITY
Retained Earnings -$617.4M -$592.8M -$502.1M
YoY Change 17.12% 18.07% 19.13%
Common Stock $781.2M $776.6M
YoY Change 13.29%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $163.7M $183.8M $185.5M
YoY Change
Total Liabilities & Shareholders Equity $204.7M $229.6M $207.6M
YoY Change -1.81% 10.61% -27.24%

Cashflow Statement

Concept 2023 Q2 2023 Q1 2022 Q1
OPERATING ACTIVITIES
Net Income -$24.63M -$30.07M -$25.33M
YoY Change -1.85% 18.72% 49.87%
Depreciation, Depletion And Amortization $703.0K $703.0K $709.0K
YoY Change -2.63% -0.85% -3.41%
Cash From Operating Activities -$27.47M -$28.00M -$27.19M
YoY Change 72.98% 2.96% 27.26%
INVESTING ACTIVITIES
Capital Expenditures $536.0K $506.0K $184.0K
YoY Change -147.18% 175.0% 425.71%
Acquisitions
YoY Change
Other Investing Activities -$47.70M $37.77M $37.93M
YoY Change -18.41% -0.42%
Cash From Investing Activities -$48.23M $37.26M $37.74M
YoY Change -19.07% -1.28% -107937.14%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 2.617M 0.000 22.00K
YoY Change 3484.93% -100.0% -99.98%
NET CHANGE
Cash From Operating Activities -27.47M -28.00M -27.19M
Cash From Investing Activities -48.23M 37.26M 37.74M
Cash From Financing Activities 2.617M 0.000 22.00K
Net Change In Cash -73.08M 9.265M 10.58M
YoY Change -3.08% -12.39% -90.7%
FREE CASH FLOW
Cash From Operating Activities -$27.47M -$28.00M -$27.19M
Capital Expenditures $536.0K $506.0K $184.0K
Free Cash Flow -$28.00M -$28.50M -$27.37M
YoY Change 89.94% 4.12% 27.91%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q1 sldb Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level1
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel1
0
CY2023Q1 dei Amendment Flag
AmendmentFlag
false
CY2023Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001707502
CY2023Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022 sldb Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level2
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel2
0
CY2023Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2022 sldb Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers In To Level2
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersInToLevel2
0
CY2023Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2023Q1 sldb Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers In To Level1
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersInToLevel1
0
CY2022 sldb Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level1
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel1
0
CY2022 sldb Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers In To Level1
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersInToLevel1
0
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2023Q1 sldb Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers In To Level2
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersInToLevel2
0
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q1 us-gaap Preferred Stock Value
PreferredStockValue
CY2023Q1 sldb Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level2
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel2
0
CY2023Q1 dei Document Type
DocumentType
10-Q
CY2023Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2023Q1 dei Document Period End Date
DocumentPeriodEndDate
2023-03-31
CY2023Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2023Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2023Q1 dei Entity File Number
EntityFileNumber
001-38360
CY2023Q1 dei Entity Registrant Name
EntityRegistrantName
Solid Biosciences Inc.
CY2023Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2023Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
90-0943402
CY2023Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
500 Rutherford Avenue
CY2023Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Third FloorCharlestown
CY2023Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
CY2023Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02129
CY2023Q1 dei City Area Code
CityAreaCode
617
CY2023Q1 dei Local Phone Number
LocalPhoneNumber
337-4680
CY2023Q1 dei Security12b Title
Security12bTitle
Common Stock $0.001 par value per share
CY2023Q1 dei Trading Symbol
TradingSymbol
SLDB
CY2023Q1 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2023Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2023Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2023Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2023Q1 dei Entity Ex Transition Period
EntityExTransitionPeriod
true
CY2023Q1 dei Entity Shell Company
EntityShellCompany
false
CY2023Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
19601539
CY2023Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
164649000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
155384000
CY2023Q1 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
20860000
CY2022Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
58338000
CY2023Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
5095000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
5916000
CY2023Q1 us-gaap Assets Current
AssetsCurrent
190604000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
219638000
CY2023Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
28306000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
28949000
CY2023Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
8607000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
9657000
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-68000
CY2023Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-592808000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-562738000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
183787000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
211666000
CY2023Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
229588000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
260252000
CY2022Q1 us-gaap Revenue From Related Parties
RevenueFromRelatedParties
1925000
CY2023Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
238000
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
175000
CY2023Q1 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
1833000
CY2022Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
1833000
CY2023Q1 us-gaap Assets
Assets
229588000
CY2022Q4 us-gaap Assets
Assets
260252000
CY2023Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
5595000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
3238000
CY2023Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
12384000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
16691000
CY2023Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1863000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1897000
CY2023Q1 sldb Finance Liabilities And Finance Lease Sale And Lease Back Liabilities Current
FinanceLiabilitiesAndFinanceLeaseSaleAndLeaseBackLiabilitiesCurrent
396000
CY2022Q4 sldb Finance Liabilities And Finance Lease Sale And Lease Back Liabilities Current
FinanceLiabilitiesAndFinanceLeaseSaleAndLeaseBackLiabilitiesCurrent
668000
CY2023Q1 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
55000
CY2022Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
14000
CY2023Q1 us-gaap Liabilities Current
LiabilitiesCurrent
20293000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
22508000
CY2023Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
23912000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
24279000
CY2023Q1 sldb Finance Liabilities And Finance Lease Sale And Lease Back Liabilities Noncurrent
FinanceLiabilitiesAndFinanceLeaseSaleAndLeaseBackLiabilitiesNoncurrent
1596000
CY2022Q4 sldb Finance Liabilities And Finance Lease Sale And Lease Back Liabilities Noncurrent
FinanceLiabilitiesAndFinanceLeaseSaleAndLeaseBackLiabilitiesNoncurrent
1703000
CY2022Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
96000
CY2023Q1 us-gaap Liabilities
Liabilities
45801000
CY2022Q4 us-gaap Liabilities
Liabilities
48586000
CY2023Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2023Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
60000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
60000000
CY2023Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
19573132
CY2023Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
19573132
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
19556732
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
19556732
CY2023Q1 us-gaap Common Stock Value
CommonStockValue
20000
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
20000
CY2023Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
776570000
CY2022Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
774452000
CY2023Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
5000
CY2023Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
24631000
CY2022Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
19945000
CY2023Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7399000
CY2022Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7352000
CY2023Q1 us-gaap Operating Expenses
OperatingExpenses
32030000
CY2022Q1 us-gaap Operating Expenses
OperatingExpenses
27297000
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-32030000
CY2022Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-25372000
CY2023Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
1678000
CY2022Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
54000
CY2023Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
282000
CY2022Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-10000
CY2023Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1960000
CY2022Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
44000
CY2023Q1 us-gaap Profit Loss
ProfitLoss
-30070000
CY2022Q1 us-gaap Profit Loss
ProfitLoss
-25328000
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.54
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.54
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.37
CY2022Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-3.37
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
19567635
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
19567635
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
7507155
CY2022Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
7507155
CY2023Q1 us-gaap Profit Loss
ProfitLoss
-30070000
CY2022Q1 us-gaap Profit Loss
ProfitLoss
-25328000
CY2023Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
73000
CY2022Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-6000
CY2023Q1 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-29997000
CY2022Q1 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-25334000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
211666000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2118000
CY2023Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
73000
CY2023Q1 us-gaap Profit Loss
ProfitLoss
-30070000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
183787000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
208211000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2612000
CY2022Q1 sldb Pre Funded Warrants Exercise During Period Value
PreFundedWarrantsExerciseDuringPeriodValue
22000
CY2022Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-6000
CY2022Q1 us-gaap Profit Loss
ProfitLoss
-25328000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
185511000
CY2023Q1 us-gaap Profit Loss
ProfitLoss
-30070000
CY2022Q1 us-gaap Profit Loss
ProfitLoss
-25328000
CY2023Q1 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
215000
CY2022Q1 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-371000
CY2023Q1 us-gaap Share Based Compensation
ShareBasedCompensation
2118000
CY2022Q1 us-gaap Share Based Compensation
ShareBasedCompensation
2612000
CY2023Q1 sldb Depreciation And Impairment Expense
DepreciationAndImpairmentExpense
1077000
CY2022Q1 sldb Depreciation And Impairment Expense
DepreciationAndImpairmentExpense
709000
CY2023Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-1261000
CY2022Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
3366000
CY2022Q1 us-gaap Increase Decrease In Accounts Receivable Related Parties
IncreaseDecreaseInAccountsReceivableRelatedParties
-96000
CY2023Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
2745000
CY2022Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
71000
CY2023Q1 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-4911000
CY2022Q1 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-445000
CY2022Q1 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-1910000
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-27995000
CY2022Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-27190000
CY2023Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
506000
CY2022Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
184000
CY2023Q1 us-gaap Payments For Proceeds From Availableforsale Securities Shortterm
PaymentsForProceedsFromAvailableforsaleSecuritiesShortterm
-37766000
CY2022Q1 us-gaap Payments For Proceeds From Availableforsale Securities Shortterm
PaymentsForProceedsFromAvailableforsaleSecuritiesShortterm
-46808000
CY2022Q1 us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
8881000
CY2023Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
37260000
CY2022Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
37743000
CY2022Q1 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
22000
CY2022Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
22000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
9265000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
10575000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
157217000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
121206000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
166482000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
131781000
CY2022Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
264000
CY2022Q4 us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
one-for-15
CY2022Q4 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.015
CY2022Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
20000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
60000000
CY2023Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-592808000
CY2023Q1 us-gaap Profit Loss
ProfitLoss
-30070000
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-27995000
CY2023Q1 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
185509000
CY2023Q1 us-gaap Restricted Cash
RestrictedCash
1833000
CY2023Q1 us-gaap Use Of Estimates
UseOfEstimates
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Use of Estimates</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The preparation of the Company’s condensed consolidated financial statements in conformity with GAAP requires management to make estimates, judgments and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting periods. Significant estimates and assumptions reflected in these condensed consolidated financial statements include, but are not limited to, estimates related to revenue recognition, the recognition of research and development expenses and equity-based compensation. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results could differ from the Company’s estimates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The full extent to which the COVID-19 pandemic will directly or indirectly impact the Company’s business, results of operations and financial condition, including clinical trials and employee-related amounts, will depend on future developments that are highly uncertain, including new information that may emerge concerning COVID-19 and the actions taken to contain</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">it or treat its impact. The Company has made estimates of the impact of COVID-19 within its financial statements and there may be changes to those estimates in future periods. Actual results could differ from the Company’s estimates.</span></p>
CY2023Q1 us-gaap Deposit Assets
DepositAssets
1833000
CY2022Q4 us-gaap Deposit Assets
DepositAssets
1833000
CY2023Q1 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
1833000
CY2022Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
1833000
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
10956000
CY2023Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
8607000
CY2023Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
164649000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
155384000
CY2022Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
129711000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
119136000
CY2023Q1 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
1833000
CY2022Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
1833000
CY2022Q1 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
2070000
CY2021Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
2070000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
166482000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
157217000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
131781000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
121206000
CY2023Q1 sldb Proceeds From Sale And Lease Back Transactions
ProceedsFromSaleAndLeaseBackTransactions
2143000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
9657000
CY2023Q1 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
19464000
CY2023Q1 us-gaap Exchange Fees
ExchangeFees
517000
CY2022Q1 us-gaap Exchange Fees
ExchangeFees
235000
CY2020Q4 sldb Common Stock Shares Issued Warrant To Purchase
CommonStockSharesIssuedWarrantToPurchase
2000
CY2020Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
49.35
CY2023Q1 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
110937000
CY2023Q1 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
20860000
CY2023Q1 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
131797000
CY2022Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
69374000
CY2022Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
58338000
CY2022Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
127712000
CY2023Q1 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3
0
CY2022 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3
0
CY2023Q1 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3
0
CY2022 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3
0
CY2023Q1 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
20855000
CY2023Q1 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
5000
CY2023Q1 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
20860000
CY2022Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
58406000
CY2022Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
68000
CY2022Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
58338000
CY2023Q1 us-gaap Available For Sale Securities Debt Maturities Next Rolling Twelve Months Amortized Cost Basis
AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsAmortizedCostBasis
20855000
CY2023Q1 us-gaap Available For Sale Securities Debt Maturities Next Rolling Twelve Months Fair Value
AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue
20860000
CY2023Q1 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
20855000
CY2023Q1 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
20860000
CY2023Q1 sldb Available For Sale Securities Weighted Average Maturity Period
AvailableForSaleSecuritiesWeightedAverageMaturityPeriod
P0Y6M
CY2022Q4 us-gaap Available For Sale Securities Debt Maturities Next Rolling Twelve Months Amortized Cost Basis
AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsAmortizedCostBasis
58406000
CY2022Q4 us-gaap Available For Sale Securities Debt Maturities Next Rolling Twelve Months Fair Value
AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue
58338000
CY2022Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
58406000
CY2022Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
58338000
CY2022 sldb Available For Sale Securities Weighted Average Maturity Period
AvailableForSaleSecuritiesWeightedAverageMaturityPeriod
P0Y6M
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
20613000
CY2023Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
10857000
CY2022Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-25328000
CY2023Q1 us-gaap Depreciation
Depreciation
703000
CY2022Q1 us-gaap Depreciation
Depreciation
709000
CY2023Q1 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
374000
CY2022Q1 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2023Q1 sldb Prepaid Research And Development Expenses Current
PrepaidResearchAndDevelopmentExpensesCurrent
2245000
CY2022Q4 sldb Prepaid Research And Development Expenses Current
PrepaidResearchAndDevelopmentExpensesCurrent
2913000
CY2023Q1 sldb Prepaid Expense And Other Assets Miscellaneous Current
PrepaidExpenseAndOtherAssetsMiscellaneousCurrent
2850000
CY2022Q4 sldb Prepaid Expense And Other Assets Miscellaneous Current
PrepaidExpenseAndOtherAssetsMiscellaneousCurrent
3003000
CY2023Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
5095000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
5916000
CY2023Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
12384000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
16691000
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.54
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.54
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
174738
CY2023Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2118000
CY2022Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2612000
CY2023Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2022Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2023Q1 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2022Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2023Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-30070000
CY2022Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-3.37
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.37
CY2023Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2955080
CY2022Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1946525

Files In Submission

Name View Source Status
sldb-20230331_cal.xml Edgar Link unprocessable
0000950170-23-020851-index-headers.html Edgar Link pending
0000950170-23-020851-index.html Edgar Link pending
0000950170-23-020851.txt Edgar Link pending
0000950170-23-020851-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
sldb-20230331.htm Edgar Link pending
sldb-20230331.xsd Edgar Link pending
sldb-ex10_2.htm Edgar Link pending
sldb-ex31_1.htm Edgar Link pending
sldb-ex31_2.htm Edgar Link pending
sldb-ex32_1.htm Edgar Link pending
sldb-ex32_2.htm Edgar Link pending
sldb-20230331_def.xml Edgar Link unprocessable
sldb-20230331_lab.xml Edgar Link unprocessable
sldb-20230331_pre.xml Edgar Link unprocessable
sldb-20230331_htm.xml Edgar Link completed